Background: Antipsychotic treatment of schizophrenia is often associated with increased rates of metabolic syndrome (MetSy), as defined by criteria for waist circumference, triglycerides,...
Introduction: Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutama...
Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. In a Phase 3 clinical ...